Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.

D.E. Ramirez-Ardila; J.C. Helmijr; M.P. Look; I. Lurkin; K. Ruigrok-Ritstier; S. van Laere; L. Dirix; F.C. Sweep; P.N. Span; S.C. Linn; J.A. Foekens; S. Sleijfer; E.M.J.J. Berns; M.P.H.M. Jansen

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.

Translated title of the contribution: Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.

D.E. Ramirez-Ardila
, J.C. Helmijr
, M.P. Look
, I. Lurkin
, K. Ruigrok-Ritstier
, S. van Laere
, L. Dirix
, F.C. Sweep
, P.N. Span
, S.C. Linn
, J.A. Foekens
, S. Sleijfer
, E.M.J.J. Berns
, M.P.H.M. Jansen

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Original language	Undefined/Unknown
Pages (from-to)	39-49
Number of pages	11
Journal	Breast Cancer Research and Treatment
Volume	139
Issue number	1
Publication status	Published - 2013

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/23592373

Cite this

Ramirez-Ardila, D. E., Helmijr, J. C., Look, M. P., Lurkin, I., Ruigrok-Ritstier, K., van Laere, S., Dirix, L., Sweep, F. C., Span, P. N., Linn, S. C., Foekens, J. A., Sleijfer, S., Berns, E. M. J. J., & Jansen, M. P. H. M. (2013). Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Research and Treatment, 139(1), 39-49. http://www.ncbi.nlm.nih.gov/pubmed/23592373

@article{99de59a6117940638a725858e8bae75d,

title = "Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.",

author = "D.E. Ramirez-Ardila and J.C. Helmijr and M.P. Look and I. Lurkin and K. Ruigrok-Ritstier and \{van Laere\}, S. and L. Dirix and F.C. Sweep and P.N. Span and S.C. Linn and J.A. Foekens and S. Sleijfer and E.M.J.J. Berns and M.P.H.M. Jansen",

year = "2013",

language = "Undefined/Unknown",

volume = "139",

pages = "39--49",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "1",

}

Ramirez-Ardila, DE, Helmijr, JC, Look, MP, Lurkin, I, Ruigrok-Ritstier, K, van Laere, S, Dirix, L, Sweep, FC, Span, PN, Linn, SC, Foekens, JA, Sleijfer, S, Berns, EMJJ & Jansen, MPHM 2013, 'Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.', Breast Cancer Research and Treatment, vol. 139, no. 1, pp. 39-49. <http://www.ncbi.nlm.nih.gov/pubmed/23592373>

TY - JOUR

T1 - Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.

AU - Ramirez-Ardila, D.E.

AU - Helmijr, J.C.

AU - Look, M.P.

AU - Lurkin, I.

AU - Ruigrok-Ritstier, K.

AU - van Laere, S.

AU - Dirix, L.

AU - Sweep, F.C.

AU - Span, P.N.

AU - Linn, S.C.

AU - Foekens, J.A.

AU - Sleijfer, S.

AU - Berns, E.M.J.J.

AU - Jansen, M.P.H.M.

PY - 2013

Y1 - 2013

M3 - Article

SN - 0167-6806

VL - 139

SP - 39

EP - 49

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -